Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02756858




Registration number
NCT02756858
Ethics application status
Date submitted
8/03/2016
Date registered
29/04/2016
Date last updated
12/01/2021

Titles & IDs
Public title
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Scientific title
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Secondary ID [1] 0 0
ANAVEX2-73-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ANAVEX2-73

Experimental: ANAVEX2-73 Oral as assigned in ANAVEX2-73-002 -


Treatment: Drugs: ANAVEX2-73
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timepoint [1] 0 0
Up to 208 weeks
Secondary outcome [1] 0 0
Score from MMSE (Mini-mental state examination score)
Timepoint [1] 0 0
Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208
Secondary outcome [2] 0 0
Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)
Timepoint [2] 0 0
Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208
Secondary outcome [3] 0 0
HAM-D Score (Hamilton Psychiatric Rating Scale for Depression)
Timepoint [3] 0 0
Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208

Eligibility
Key inclusion criteria
- Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73
Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and
Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With
a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)
Minimum age
55 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design
With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in
Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label
Follow-Up Period (ANAVEX2-73-002)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2020
Sample size
Target
Accrual to date
Final
21
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Melbourne Health - The Royal Melbourne Hospital - Melbourne
Recruitment hospital [2] 0 0
Austin Health - Heidelberg Repatriation Hospital - Melbourne
Recruitment hospital [3] 0 0
Caulfield Hospital - Melbourne
Recruitment hospital [4] 0 0
Nucleus Network- Centre for Clinical Studies - Melbourne
Recruitment hospital [5] 0 0
St. Vincent's Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3050 - Melbourne
Recruitment postcode(s) [2] 0 0
3084 - Melbourne
Recruitment postcode(s) [3] 0 0
3162 - Melbourne
Recruitment postcode(s) [4] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Anavex Life Sciences Corp.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This open label extension study is designed to provide continued access to ANAVEX 2-73 for
eligible subjects with mild to moderate Alzheimer's Disease who have previously participated
in the Anavex sponsored study ANAVEX2-73-002.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02756858
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02756858